Viewing nowJanumax Tablet 25 Milligrams (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.

MFDS item code 202400103 · Approved 2024.01.15 · Insurance code 644004770
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication assists in blood sugar control in patients with type 2 diabetes by augmenting dietary and exercise regimens. It can be used alone or in combination with other medications, contributing to the effective management of blood sugar and the prevention of complications.
Administer this drug at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions, so if symptoms such as skin rashes or difficulty breathing occur, it should be discontinued immediately and a doctor consulted. There is a risk of acute pancreatitis with this medication, so monitor for symptoms of pancreatitis such as abdominal pain or vomiting, and if suspected, stop the medication at once. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients with a history of hypersensitivity to this medication or its components. In patients with decreased renal function, dosage adjustment is required, and regular kidney function tests are important. During treatment with this drug, side effects such as upper respiratory infections, pharyngitis, headaches, diarrhea, nausea, etc., may occur; inform healthcare personnel if symptoms persist or worsen. When taken with insulin or sulfonylureas, there is an increased risk of hypoglycemia, so blood sugar levels should be checked frequently, and dosage adjustments may be necessary. If severe joint pain or skin blisters develop during treatment, discontinue use immediately and consult a doctor. Pregnant or breastfeeding women should avoid using this medication, and safety in pediatric patients under 18 years has not been established. In case of overdose, seek medical attention immediately for appropriate treatment; this medication can be partially removed by hemodialysis.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative dermatitis, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory tract infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. Additionally, it is advisable to store the medication at room temperature between 1°C and 30°C. This storage method helps maintain the drug's efficacy.
Pink, double-convex, round, film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.